Compare Adaptive Biotechnologies Corp (ADPT) vs Marqeta Inc (MQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Marqeta Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Marqeta Inc trades at $15.59 (market cap $1.77B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | MQ | |
|---|---|---|
Market Cap | $3.33B | $1.77B |
Sector | Health | Technology |
52-Week High | $22.37 | $27.32 |
52-Week Low | $10.24 | $15.04 |
Enterprise Value | $3.19B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Marqeta (MQ) trades at $15.93, down 8.63% on the day, with a bullish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split effective July 1, 2026. Q1 2026 earnings beat expectations with EPS of $0.08 versus -$0.0136 forecast, though Q4 2025 missed. Revenue trends show recovery from 2024's $507M to $625M in 2025, with net income narrowing losses. Analyst consensus is a $19 price target with 32% buy ratings.
The outlook hinges on execution of European expansion and credit product growth, but high P/E of 420.88 reflects significant growth expectations. Risks include ongoing profitability challenges, competitive fintech pressure, and shareholder litigation. Institutional sentiment is cautiously optimistic given the price target upside, but the stock remains speculative until sustained profitability is achieved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
